Royalty Pharma (RPRX) Other financing activities (2020 - 2026)

Royalty Pharma has disclosed Other financing activities across 5 years of filings, most recently posting -$226000.0 for Q1 2026.

• Other financing activities for Q1 2026 came in at -$226000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.0 million (down 109.31% YoY), and the FY2025 annual result was -$1.8 million, down 114.19% from the prior year.
• Other financing activities came in at -$226000.0 for Q1 2026 at Royalty Pharma, up from -$15.3 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $21.6 million in Q4 2024 to a low of -$15.3 million in Q4 2025.
• The 3-year median for Other financing activities is $2000.0 (2024), against an average of $3.9 million.
• Peak annual rise in Other financing activities reached 677050.0% in 2025, while the deepest fall reached 170.85% in 2025.
• Royalty Pharma's Other financing activities stood at $21.6 million in 2024, then sank by 170.85% to -$15.3 million in 2025, then jumped by 98.53% to -$226000.0 in 2026.
• The last three Other financing activities figures came in at -$226000.0 (Q1 2026), -$15.3 million (Q4 2025), and $13.5 million (Q3 2025), per Business Quant data.